Emergent BioSolutions (EBS)
Supplies naloxone sprays and government-procured medical countermeasures for public-health emergencies.
Something off on this page? Send us feedback.
Sells NARCAN and KLOXXADO naloxone nasal sprays alongside anthrax, smallpox, mpox, Ebola, and other emergency countermeasures. Revenue is shaped by commercial overdose treatment, U.S. government procurement, external bioservices, and contract or grant funding.
Provides preparedness and response products for public-health threats, with Commercial Products centered on NARCAN and KLOXXADO naloxone nasal sprays. MCM Products include anthrax countermeasures such as BioThrax, CYFENDUS, ANTHRASIL and raxibacumab, smallpox countermeasures such as ACAM2000, CNJ-016 and TEMBEXA, plus BAT and Ebanga.
Sales are concentrated in the United States and Canada for naloxone, while the medical-countermeasure portfolio is built around domestic and international government customers. The current portfolio combines the original BioThrax franchise with products added through acquisitions and licensing.
Execution depends on regulated manufacturing, quality systems and government-contract performance after a restructuring that reduced the services footprint. U.S. government procurement, audit rights and contract changes remain structural features of the business.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $12 | Target: $10 |
| Mar 9, 2026 | H.C. Wainwright | Target | Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $139.7M · Total debt $581.8M · Total assets $1.12B · Shareholders' equity $341.4M
- Revenue
- $234.3M
- Operating income
- −$125.1M
- Net income
- −$180.2M
No dividends on record.
| Institutions | 89.30% | 45.79M shares | |
|---|---|---|---|
| 201 holders · as of Jun 30, 2026 | |||
| Insiders | 6.00% | 3.08M shares | |
| 18 holders · as of Aug 12, 2026 | |||
| Other | 4.70% | 2.41M shares | |
| remainder | |||
51.27M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.20% | 4.72M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 6.00% | 3.08M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.71% | 2.93M | as of Jun 30, 2026 |
American Century Companies IncInstitution | 5.40% | 2.77M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.29% | 2.20M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Paul Anthony Williams | officer: SVP, Products Business | −3,000 | $8.40 |
| May 1, 2026 | Kathryn C. Zoon | director | −17,202 | $8.40 |
| Apr 30, 2026 | Keith Katkin | director | −15,481 | $8.28 |
| May 1, 2026 | Donald W. DeGolyer | director | −15,481 | $8.40 |
| May 1, 2026 | Sujata Tyagi Dayal | director | −13,761 | $8.40 |
- SIGA
Smallpox antiviral supplier for preparedness stockpiles
- Teva (ADR)
Generic naloxone nasal spray rival to Narcan
- Amphastar Pharmaceuticals
Branded naloxone nasal spray and injection competitor
- Amneal Pharmaceuticals
OTC generic naloxone equivalent to Narcan
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Emergent BioSolutions | $6.86 | +1.63% | $338.0M | — | — | 0.4 | +66.3% |
| SIGA | $3.26 | −0.15% | $226.6M | — | — | 4.2 | −49.5% |
| Teva (ADR) | $39.32 | −0.43% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Amphastar Pharmaceuticals | $24.32 | −0.16% | $1.08B | 14.5 | 7.7 | 1.5 | +5.4% |
| Amneal Pharmaceuticals | $19.50 | 0.00% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Median | 41.4 | 14.1 | 2.4 | +2.3% |